Acurx Pharmaceuticals, Inc.

ACXP ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $7.6M $3.7M $7.5M $9.1M $13.0M $3.2M $2.5M
Accounts Receivable
Inventory
Total Current Assets
Property, Plant & Equipment
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $7.7M $3.9M $7.7M $9.4M $13.3M $3.2M
Liabilities
Accounts Payable
Total Current Liabilities $2.4M $3.2M $3.0M $2.1M $843.9K $472.6K
Long-Term Debt
Total Liabilities $2.4M $3.2M $3.0M $2.1M $843.9K $522.4K
Stockholders' Equity
Retained Earnings $-75.3M $-67.3M $-53.2M $-38.6M $-26.5M $-13.8M
Total Stockholders' Equity $5.3M $615.1K $4.7M $7.3M $12.4M $2.7M